UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):   April 12, 2019
 
AYTU BIOSCIENCE, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware
001-38247
47-0883144
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
373 Inverness Parkway, Suite 206
Englewood, CO 80112
 
(Address of principal executive offices, including Zip Code)
 
Registrant’s telephone number, including area code: (720) 437-6580
 
N/A
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
 
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
The 2019 annual meeting of stockholders for Aytu BioScience, Inc. was held on April 12, 2019. Of the 12,455,435 shares outstanding on the record date for the meeting, a total of 9,446,603 shares were present or represented at the meeting. The matters voted on and the results of the votes are as follows:
 
1. 
Our stockholders elected six members to our board of directors as follows:
 
Members
 
Number of Votes Cast For
 
 
Number of Votes Cast Against
 
 
Number of Votes Withheld
 
 
Number of Broker Non-Votes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joshua R. Disbrow
    5,149,902  
    0  
    235,142  
    4,061,559  
 
       
       
       
       
Gary V. Cantrell
    5,139,275  
    0  
    245,769  
    4,061,559  
 
       
       
       
       
Carl C. Dockery
    5,173,759  
    0  
    211,285  
    4,061,559  
 
       
       
       
       
John A. Donofrio, Jr.
    5,183,997  
    0  
    201,047  
    4,061,559  
 
       
       
       
       
Michael E. Macaluso
    5,140,142  
    0  
    244,902  
    4,061,559  
 
       
       
       
       
Ketan B. Mehta
    5,148,977  
    0  
    236,067  
    4,061,559  
 
2. 
The “Exchange Agreement Proposal” described in the Company’s definitive proxy statement was approved with 5,149,752 votes in favor, 232,435 votes against and 2,857 abstentions. The number of broker non-votes was 4,061,559.
3. 
The ratification of the appointment of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2019 was approved with 9,040,394 votes in favor, 182,903 votes against and 223,306 abstentions.
4. 
The proposal to approve the adjournment of the Annual Meeting, if necessary, to continue to solicit votes for the Exchange Agreement Proposal was approved with 8,192,040 votes in favor, 1,159,918 votes against and 94,645 abstentions.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
AYTU BIOSCIENCE, INC.
 
 
 
 
 
 
 
 
 
 
Date:
April 15, 2019
 
By:
/s/ Joshua R. Disbrow
 
 
 
 
Joshua R. Disbrow
 
 
 
 
Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AYTU BioPharma Charts.
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AYTU BioPharma Charts.